These data suggest that therapeutic targeting of the SOCS1 pathway, through the use of peptides that mimic SOCS1 activity, may serve as a novel approach for the treatment of lymphocyte mediated autoimmunity. The gene discussed is SOCS1; the disease is Autoimmunity.